April 14, 2026 · Form 4 insider transaction
Calvin Sandra sold 21,977 shares of Travere Therapeutics, Inc. at $41.07 per share, a transaction worth $902.6K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.